Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL185189 | 0.84 | GABRA1 (0.44) | GABRA1GABRB2PNMTSLC6A2SLC6A3 | |
| SCHEMBL1777119 | 0.77 | GABRA1 (0.39) | GABRA1GABRB2SLC6A2SLC6A3TAAR1 | |
| SCHEMBL1777260 | 0.77 | GABRA1 (0.39) | GABRA1GABRB2SLC6A2SLC6A3TAAR1 | |
| SCHEMBL455459 | 0.76 | — | — | |
| SCHEMBL28038270 | 0.75 | GABRA1 (0.38) | GABRA1GABRB2SLC6A2SLC6A3TAAR1 | |
| SCHEMBL1777957 | 0.75 | GABRA1 (0.38) | GABRA1GABRB2SLC6A2SLC6A3TAAR1 | |
| SCHEMBL1776725 | 0.73 | GABRA1 (0.36) | GABRA1GABRB2 | |
| SCHEMBL27769168 | 0.73 | — | — | |
| SCHEMBL2698334 | 0.72 | — | — | |
| SCHEMBL5011449 | 0.72 | ALDH1A1 (0.38) | SLC6A2SLC6A3TAAR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632929-A1 | N-HETEROCYCLIC CARBENE COMPLEXES, THEIR PREPARATION AND USE | BASF SE (DE) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012056419-A1 | N-HETEROCYCLIC CARBENE COMPLEXES, THEIR PREPARATION AND USE | BASF SE (DE) | 2012-05-03 | — | — | WO | disclosed |
| US-20120108819-A1 | N-Heterocyclic Carbene Complexes, Their Preparation And Use | BASF SE (DE) | 2012-05-03 | — | — | US | disclosed |
| US-4169106-A | Antiarrhythmic N,N'-bis(phenylcarbamoylalkyl)amidines | COOPER LABORATORIES, INC. (US) | 1979-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108819-A1 | N-Heterocyclic Carbene Complexes, Their Preparation And Use | CYCS, CYC1, CBR1 | GABRA1 2613/4885GABRB2 2787/4885PNMT 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.